Theranostics Market Share, Size, Trends, Industry Analysis Report, By Disease (Neurological Disorders, Cardiovascular Diseases, Oncology Disorders, Immunological Disorders), By Technology, By End-User, By Region, Segments & Forecast, 2023 – 2032

Theranostics Market Share, Size, Trends, Industry Analysis Report, By Disease (Neurological Disorders, Cardiovascular Diseases, Oncology Disorders, Immunological Disorders), By Technology, By End-User, By Region, Segments & Forecast, 2023 – 2032

The global theranostics market size is expected treach USD 3,096.47 Million by 2032, according ta new study by Polaris Market Research. The report “Theranostics Market Share, Size, Trends, Industry Analysis Report, By Disease (Neurological Disorders, Cardiovascular Diseases, Oncology Disorders, Immunological Disorders), By Technology, By End-User, By Region, Segments & Forecast, 2019 – 2032” gives a detailed insight intcurrent market dynamics and provides analysis on future market growth.

Theranostics is expected tgrow at a quick rate owing tIncreasing incidences of cancer and other chronic illness across the globe. Other supporting factors are projected treduce the time for medical trials and increase the need for low-cost tumor diagnosis among the patients of merging economy countries.

Theranostics is a field of medicine that combines diagnostic and therapeutic capabilities tprovide personalized treatment options for patients. The term is a combination of ""therapy"" and ""diagnostics."" Theranostics involves the use of targeted therapies that are tailored tan individual patient's unique characteristics, such as their genetic makeup, molecular profile, and disease stage.

The goal of the therapy is tprovide a more precise and effective approach tdisease management by identifying the most appropriate treatment for each patient based on their specific needs. This approach can help reduce side effects and improve outcomes by targeting the underlying mechanisms of disease.

There are several limiting factors that affect the growth and adoption of theranostics in the market, including high development and production costs, limited reimbursement, complex regulatory environment, limited clinical evidence, limited physician and patient awareness, and challenges in integrating diagnostics and therapeutics. Overall, these limiting factors can slow the growth and adoption of theranostics in the market, and addressing these issues will be crucial for realizing the full potential of this approach tpersonalized medicine.

Overall, the impact of COVID-19 on the theranostics market has been mixed, with both positive and negative effects. On the positive side, the pandemic has created a greater awareness of the importance of personalized medicine and targeted therapies, which are the core of the theranostics approach. However, the pandemic has alsresulted in delays in clinical trials and approvals, as well as disruptions in the production and distribution of theranostic products.

Report Highlights

The Oncology Disorders segment accounted for the largest market share in 2022. Overall, the oncology segment of the theranostics market is expected tcontinue tgrow, driven by increasing awareness of personalized medicine and advances in molecular diagnostics and targeted therapies.

Based on Technology, the Polymerase Chain Reaction (PCR) segment is anticipated tgrow quickly over the forecast period. The PCR segment of the theranostics market is expected tcontinue tgrow, driven by the increasing demand for rapid and accurate diagnostic tests and the development of new PCR-based technologies, such as digital PCR and droplet digital PCR.

The Hospitals and Clinics segment is accounted twitness the fastest growth rate in the forecast period. The segment growth can be attributed tvarious factors such as rising number of theranostics patients requiring the diagnosis treatment. The increasing demand for targeted diagnostic and therapeutic solutions, coupled with the growing prevalence of chronic diseases, is expected tfuel the growth of the theranostics market in the coming years.

North America region is leading the market in terms of revenue share for the year 2022 and the coming years. The major factors for the region's growth are the increasing demand for personalized medicine and the growing prevalence of chronic diseases. The presence of key market players and well-established healthcare infrastructure are expected tfuel the market growth in the region further.

Polaris Market Research has segmented the theranostics Market report based on disease, technology, end-user, and region:

Theranostics Market, Disease Outlook (Revenue - USD Million, 2019 - 2032)

Neurological Disorders

Cardiovascular Diseases

Oncology Disorders

Immunological Disorders

Theranostics Market, Technology Outlook (Revenue - USD Million, 2019 - 2032)

Polymerase Chain Reaction (PCR)

In Situ Hybridization (ISH)

Immunohistochemistry (IHC)

Sequencing

Theranostics Market, End-User Outlook (Revenue - USD Million, 2019- 2032)

Hospitals and Clinics

Diagnostics Laboratories

Others

Theranostics Market, Regional Outlook (Revenue - USD Million, 2019 - 2032)

North America

U.S.

Canada

Europe

Germany

UK

France

Italy

Spain

Russia

Netherlands

Asia Pacific

China

India

Japan

South Korea

Indonesia

Malaysia

Latin America

Argentina

Brazil

Mexico

Middle East & Africa

UAE

Saudi Arabia

Israel

South Africa